Drug intelligence / Profile preview

RIST8309

Development stage: Unknown
Lead developer: Aristea Therapeutics
Modality: Small Molecules

Overview

**RIST8309** is a small molecule CXCR2 antagonist developed by Aristea Therapeutics, a company that ceased operations following safety issues with its lead program. CXCR2 (C-X-C chemokine receptor type 2) is a G protein-coupled receptor involved in neutrophil chemotaxis and inflammation; antagonism inhibits these pathways, potentially for autoimmune or inflammatory diseases. Specific primary indications were undisclosed, and no clinical trial data or efficacy results are publicly available. Development was discontinued, with no further advancement reported.

Targets

CXCR2 (C-X-C Motif Chemokine Receptor 2)

Beyond the preview

Go deeper on RIST8309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIST8309.

Explore the full profile